卡铂联合紫杉醇腹腔化疗对高级别浆液性卵巢癌的疗效

doi:10.3969/j.issn.2095-9400.2021.07.011

摘要
图/表
参考文献(13)
相关文章 (7)

全文: PDF (1261 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究卡铂联合紫杉醇腹腔化疗对高级别浆液性卵巢癌（HGSOC）的疗效。方法：选取2015年1月至2019 年7月温州医科大学附属第一医院收治的110 例HGSOC患者，根据治疗方式不同分为卡铂联合紫杉醇静脉化疗组（A组）34例，卡铂联合紫杉醇腹腔化疗组（B组）30例，顺铂联合紫杉醇腹腔化疗组（C组）28例，传统化疗药（环磷酰胺、阿霉素等）静脉化疗组（D组）18例。比较各组患者生存情况及不良反应，评判卡铂联合紫杉醇腹腔化疗治疗HGSOC的实用性、有效性与安全性。结果：A组、B组、C组5年生存率较D组均显著增高，组间差异有统计学意义（P ＜0.05）；B组、C组3年生存率亦较D组增高，组间差异有统计学意义（P ＜0.05）；而A组、B组、C组间3年、5年生存率差异均无统计学意义（P ＞0.05）。4组间III、IV级骨髓抑制的发生率差异均无统计学意义（P ＞0.05）。III、IV级胃肠道反应与腹痛发生情况：C组、D组分别与A组、B组比较，差异均有统计学意义（P ＜0.05），但A组与B组间、C组与D组间差异无统计学意义（P ＞0.05）。4组间皮疹发病率差异无统计学意义（P ＞0.05）。结论：卡铂联合紫杉醇腹腔化疗可以延长HGSOC患者的生存时间，提升临床治疗效果，且不良反应较小。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	来泽
	邹阮敏
	袁宗杰
	屠馨予
	张俊伟
	黄嘉恒
	薛向阳

关键词 ：高级别浆液性卵巢癌, 腹腔化疗, 卡铂, 紫杉醇, 生存率

Abstract：Objective: To investigate the curative effect of carboplatin/paclitaxel intraperitoneal chemotherapy on high-grade serous ovarian cancer (HGSOC). Methods: According to the diagnostic result given by senior pathologists from our hospital, 110 cases of the most typical high-grade serous ovarian cancer were selected from numerous gynecological tumor slices of the First Affiliated Hospital of Wenzhou Medical University from January 2015 to July 2019. Considering their clinical data, these patients were assigned to four groups. Group A included 34 patients treated by paclitaxel combined with carboplatin intravenous chemotherapy;group B was 30 patients by paclitaxel combined carboplatin intraperitoneal chemotherapy; group C included 28 patients by paclitaxel combined with cisplatin intraperitoneal chemotherapy and group D was intravenous group,including 18 patients treated with traditional chemotherapy drugs (cyclophosphamide, adriamycin, etc.). The effectiveness and safety of carboplatin /paclitaxel intraperitoneal chemotherapy in high-grade serous ovarian cancer (HGSOC) were evaluated by comparing the four groups in the survival rate and side effects. Results: The 5-year survival rate of group A, group B, and group C was significantly higher than that of group D, with statistical difference between each group (P<0.05). The 3-year survival rate of group B and C was also higher than that of group D, with statistical difference between the groups (P<0.05).However, the 3-year and 5-year survival rates between groups A, B, and C showed no statistical difference (P>0.05).The incidence of grade III, IV bone marrow suppression was the highest in group D without significant difference among the four groups (P>0.05). The incidence of grade III, IV gastrointestinal reactions and abdominal pain was significantly different (P<0.05), but with no difference either between group A and group B or between group C and group D (P>0.05). And there was no significant difference in the incidence of rash among the four groups (P>0.05). Conclusion: Compared with cisplatin, carboplatin combined with paclitaxel intraperitoneal chemotherapy can prolong the survival time of patients with HGSOC, improve the treatment effectiveness and have fewer side effects, which can provide reference for future clinical chemotherapy.

Key words： high-grade serous ovarian cancer intraperitoneal chemotherapy carboplatin paclitaxel survival rate

收稿日期: 2020-09-09

通讯作者: 薛向阳，教授 E-mail: wzxxy001@163.com。

作者简介: 来泽，本科生，Email：251741483@qq.com。

链接本文:

https://xb.wmu.edu.cn/CN/10.3969/j.issn.2095-9400.2021.07.011 或 https://xb.wmu.edu.cn/CN/Y2021/V51/I7/578

[1] 周路, 余征, 覃强, 等. 卵巢癌组织中FGF8b表达与EMT的关系及临床意义[J]. 临床肿瘤学杂志, 2020, 25(6): 532-537.
[2] LI L, BI X, SUN H, et al. Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy[J]. J Ovarian Res, 2018, 11(1): 64.
[3] ORR B, EDWARDS R P. Diagnosis and treatment of ovarian cancer[J]. Hematol Oncol Clin North Am, 2018, 32(6): 943-964.
[4] MAHMOOD R D, MORGAN R D, EDMONDSON R J, et al.First-Line management of advanced high-grade serous ovarian cancer[J]. Curr Oncol Rep, 2020, 22(6): 64.
[5] KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84.
[6] WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41:3-14.
[7] MATULONIS U A, SOOD A K, FALLOWFIELD L, et al.Ovarian cancer[J]. Nat Rev Dis Primers, 2016, 2: 16061.
[8] STEWART C, RALYEA C, LOCKWOOD S. Ovarian cancer:an integrated review[J]. Semin Oncol Nurs, 2019, 35(2):151-156.
[9] VAN DRIEL W J, KOOLE S N, SIKORSKA K, et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med, 2018, 378(3): 230-240.
[10] 韩冰, 赵倩, 海盼盼, 等. 卡铂腹腔化疗在晚期卵巢癌患者中的应用研究[J]. 中国妇产科临床杂志, 2020, 21(3): 269-271.
[11] OSWALD A J, GOURLEY C. Intraperitoneal chemotherapy:historic anomaly or hope for the future?[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 484-492.
[12] PROVENCHER D M, GALLAGHER C J, PARULEKAR W R, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer[J]. Ann Oncol, 2018, 29(2): 431-438.
[13] WALKER J L, BRADY M F, WENZEL L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study[J]. J Clin Oncol, 2019, 37(16): 1380-1390.